Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by the presence of auto-antibodies against nuclear antigens, as well as the deposition of immune complexes, and chronic inflammation of target organs such as the skin, joints, and kidneys. Animal models continue to play a crucial role in understanding disease mechanisms and evaluating novel treatment methods. GemPharmatech has developed a humanized SLE mouse model by transferring PBMCs from SLE patients into immunodeficient mice (NCG mice). This resulted in high levels of human auto-antibodies and renal immune complex deposition. Furthermore, this model responded to B-cell directed therapeutic antibodies, which demonstrates its value and potential in evaluating novel therapeutic modalities.